IOVA

Iovance Biotherapeutics, Inc.

16.79 USD
0.00 (0.00%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Iovance Biotherapeutics, Inc. stock is up 108.31% since 30 days ago. The next earnings date is May 7, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 36.36% of the previous 10 March’s closed higher than February. In the last 10 Unusual Options Trades, there were 10 CALLs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
01 Mar 14:57 01 Mar, 2024 15.00 CALL 155 1631
01 Mar 14:57 21 Jun, 2024 24.00 CALL 1566 1052
01 Mar 15:02 19 Apr, 2024 18.00 CALL 178 6238
01 Mar 15:10 21 Jun, 2024 22.00 CALL 1500 333
01 Mar 15:22 21 Jun, 2024 7.50 CALL 100 5337
01 Mar 15:24 15 Mar, 2024 10.00 CALL 100 13577
01 Mar 20:09 01 Mar, 2024 16.00 CALL 480 1828
01 Mar 20:09 01 Mar, 2024 16.00 CALL 768 1828
01 Mar 20:21 15 Mar, 2024 4.00 CALL 30 498
01 Mar 20:48 21 Jun, 2024 24.00 CALL 229 1052

About Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc. focuses on developing and commercializing cancer immunotherapy products. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma. The company was incorporated in 2007 and is headquartered in San Carlos, California.

  • HC Wainwright & Co.
    Thu Feb 29, 15:36
    buy
    confirm
  • Goldman Sachs
    Thu Feb 29, 10:00
    buy
    confirm
  • Barclays
    Thu Feb 29, 08:40
    buy
    confirm
  • Goldman Sachs
    Wed Feb 21, 11:14
    buy
    confirm
  • JP Morgan
    Tue Feb 20, 13:10
    buy
    confirm
  • Wells Fargo
    Tue Feb 20, 11:42
    buy
    confirm
  • Goldman Sachs
    Tue Feb 20, 10:32
    buy
    confirm
  • Piper Sandler
    Tue Feb 20, 10:18
    buy
    confirm
  • Chardan Capital
    Tue Feb 20, 04:57
    buy
    confirm